Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Profound Medical Corp

Healthcare CA PRN

7.3CAD
0.23(3.25%)

Last update at 2026-03-10T20:00:00Z

Day Range

7.107.73
LowHigh

52 Week Range

5.2312.40
LowHigh

Fundamentals

  • Previous Close 7.07
  • Market Cap317.56M
  • Volume19447
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-41.54100M
  • Revenue TTM14.30M
  • Revenue Per Share TTM0.49
  • Gross Profit TTM 10.36M
  • Diluted EPS TTM-1.7

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -27.81800M -28.69700M -28.38200M -30.59400M -21.57700M
Minority interest - - - - -
Net income -27.81600M -28.56900M -28.66900M -30.69900M -21.62200M
Selling general administrative 23.13M 9.17M 9.46M 10.31M 7.57M
Selling and marketing expenses - 9.45M 8.47M 7.65M 4.86M
Gross profit 7.04M 4.38M 3.02M 2.95M 3.47M
Reconciled depreciation 0.94M 1.15M 1.60M 1.88M 1.54M
Ebit -33.06200M -27.92700M -29.60200M -30.29100M -18.86300M
Ebitda -32.12600M -26.99800M -25.47400M -28.41200M -16.63300M
Depreciation and amortization 0.94M 0.93M 4.13M 1.88M 2.23M
Non operating income net other - - - - -
Operating income -33.06200M -28.61600M -29.60200M -30.29100M -18.86300M
Other operating expenses 43.74M 35.81M 36.28M 37.16M 26.17M
Interest expense - 0.77M 0.17M 0.30M 0.54M
Tax provision -0.00200M -0.12800M 0.29M 0.10M 0.04M
Interest income 5.24M 1.64M 3.45M 0.14M 2.62M
Net interest income 1.44M 0.73M 0.92M -0.31000M 0.15M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.00200M -0.12800M 0.29M 0.10M 0.04M
Total revenue 10.68M 7.20M 6.68M 6.87M 7.30M
Total operating expenses 40.10M 33.00M 32.62M 33.24M 22.34M
Cost of revenue 3.64M 2.82M 3.66M 3.92M 3.83M
Total other income expense net 5.24M -0.08100M 1.22M -0.30300M -2.71400M
Discontinued operations - - - - -
Net income from continuing ops -27.81600M -28.56900M -28.66900M -30.69900M -21.62200M
Net income applicable to common shares -27.81600M -28.32300M -28.66900M -30.69900M -21.62200M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 70.23M 43.91M 64.42M 86.78M 104.60M
Intangible assets 0.26M 0.49M 0.68M 1.44M 1.90M
Earning assets - - - - -
Other current assets - 1.41M 1.22M 1.15M 1.07M
Total liab 9.81M 12.73M 12.42M 6.16M 7.25M
Total stockholder equity 60.42M 31.18M 52.00M 80.62M 97.35M
Deferred long term liab - - - - -
Other current liab 0.33M - 0.92M 0.25M 0.76M
Common stock - 217.39M 205.82M 219.58M 211.53M
Capital stock 281.55M 217.39M 205.82M 219.58M 211.53M
Retained earnings -245.17000M -217.93100M -189.36200M -160.69300M -129.99400M
Other liab - - 0.76M 0.88M 1.08M
Good will - - 0.00000M 2.69M 2.68M
Other assets - - - 3.62M -
Cash 54.91M 26.21M 46.52M 67.15M 83.91M
Cash and equivalents - - - - -
Total current liabilities 6.57M 6.37M 4.18M 4.16M 4.81M
Current deferred revenue - 0.72M 0.47M 0.48M 0.36M
Net debt - -18.27200M -38.28700M -65.77500M -82.23700M
Short term debt - 2.36M 0.76M 0.25M 0.31M
Short long term debt 1.74M 2.10M 0.52M - -
Short long term debt total - 7.94M 8.23M 1.38M 1.68M
Other stockholder equity - 19.69M 18.70M 16.99M 11.25M
Property plant equipment - - 1.72M 1.90M 2.28M
Total current assets 69.06M 41.90M 62.02M 77.12M 97.74M
Long term investments - - - - -
Net tangible assets - - 51.32M 76.49M 92.77M
Short term investments - - - - -
Net receivables 6.58M 7.29M 6.34M 1.41M 7.43M
Long term debt 2.92M 5.00M 6.65M - 0.00000M
Inventory 5.80M 6.99M 7.94M 7.41M 5.33M
Accounts payable 1.32M 3.28M 2.03M 3.18M 3.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 12.03M 16.84M 4.75M 4.57M
Additional paid in capital - - - - -
Common stock total equity - - - - 211.53M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 3.62M -
Deferred long term asset charges - - - - -
Non current assets total 1.17M 2.02M 2.40M 9.65M 6.86M
Capital lease obligations 0.46M 0.84M 1.06M 1.38M 1.68M
Long term debt total - - 7.47M 1.13M 1.36M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - 0.00000M -0.59300M -0.35000M
Change to liabilities - - -0.56600M -0.35600M 0.28M
Total cashflows from investing activities - - 0.00000M -0.59300M -0.35000M
Net borrowings -2.56000M -0.91200M 6.92M -0.38600M -9.60600M
Total cash from financing activities 54.70M 1.46M 7.03M 5.95M 87.43M
Change to operating activities - - -2.08600M -0.01300M 1.25M
Net income -27.81600M -28.32300M -28.66900M -30.69900M -21.62200M
Change in cash 28.70M -20.30400M -20.63500M -16.76100M 69.11M
Begin period cash flow 26.21M 46.52M 67.15M 83.91M 14.80M
End period cash flow 54.91M 26.21M 46.52M 67.15M 83.91M
Total cash from operating activities -23.45300M -22.60900M -25.80000M -22.36000M -20.57400M
Issuance of capital stock 62.11M 0.00000M - 0.00000M 85.52M
Depreciation 0.94M 1.15M 1.60M 1.88M 1.54M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 0.66M 0.35M -1.86400M -2.49100M -2.14100M
Change to account receivables 0.19M -1.41300M -1.42400M 2.00M -4.02800M
Sale purchase of stock 62.15M 2.67M 0.26M 6.43M 103.68M
Other cashflows from financing activities -4.85000M 2.67M 7.39M 6.33M 11.52M
Change to netincome - - 6.89M 7.34M 4.14M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.59M 0.35M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.59M 0.54M -5.62900M -0.87700M -4.63500M
Stock based compensation 2.58M 3.42M 4.24M 7.21M 3.02M
Other non cash items 0.26M 0.38M 2.66M 0.13M 1.13M
Free cash flow -23.45300M -22.29700M -25.80000M -22.95300M -20.92400M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PRN
Profound Medical Corp		 0.23 3.25% 7.30 - - 22.21 7.67 15.83 -7.9326

Reports Covered

Stock Research & News

View All

Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

Profound Medical Corp

2400 Skymark Avenue, Mississauga, ON, Canada, L4W 5K5

Key Executives

Name Title Year Born
Dr. Arun Swarup Menawat MBA, Ph.D. Chairman & CEO 1955
Mr. Rashed Dewan Chief Financial Officer 1968
Dr. Mathieu Burtnyk Sr. VP of Product Leader TULSA-PRO 1982
Mr. Stephen Kilmer Investor Relations NA
Mr. Hartmut Warnken Chief Commercial Officer of OUS NA
Mr. Jacques F. Cornet Sr. VP & Product Leader Sonalleve 1956
Mr. Michael Mydra VP & Head of Global Market Access NA
Mr. Abbey Goodman Chief Commercial Officer of US NA
Mr. Matthew Sobczyk C.A., CPA Assistant Corp. Controller NA
Mr. Levant Tinaz Software Developer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.